1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for
Study
1.2.3.
Key Market
Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Lung Cancer Genomic Testing Medicine Market
Outlook
4.1.
Market Size &
Forecast
4.1.1.
By Value
4.2.
Market Share & Forecast
4.2.1. By Technology
(Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ
Hybridization, and Others)
4.2.2. By Sample Type
(Tissue Biopsy and Liquid Biopsy)
4.2.3. By Panel Type
(Multi-Gene Panel and Single-Gene Panel)
4.2.4. By End-User
(Research Organization, Hospitals & Clinics, Diagnostic Laboratories,
Others)
4.2.5.
By Region
4.2.6.
By Company (2023)
4.3.
Market Map
4.3.1.
By Technology
4.3.2.
By Sample Type
4.3.3.
By Panel Type
4.3.4.
By End-User
4.3.5.
By Region
5. Asia Pacific Lung Cancer Genomic Testing Medicine Market
Outlook
5.1.
Market Size &
Forecast
5.1.1.
By Value
5.2.
Market Share &
Forecast
5.2.1.
By Technology
5.2.2. By Sample Type
5.2.3.
By Panel Type
5.2.4. By End-User
5.2.5.
By Country
5.3.
Asia Pacific:
Country Analysis
5.3.1.
China Lung Cancer
Genomic Testing Medicine Market Outlook
5.3.1.1.
Market Size & Forecast
5.3.1.1.1.
By Value
5.3.1.2.
Market Share & Forecast
5.3.1.2.1.
By Technology
5.3.1.2.2.
By Sample Type
5.3.1.2.3.
By Panel Type
5.3.1.2.4.
By End-User
5.3.2.
India Lung Cancer
Genomic Testing Medicine Market Outlook
5.3.2.1.
Market Size & Forecast
5.3.2.1.1.
By Value
5.3.2.2.
Market Share & Forecast
5.3.2.2.1.
By Technology
5.3.2.2.2.
By Sample Type
5.3.2.2.3.
By Panel Type
5.3.2.2.4.
By End-User
5.3.3.
Australia Lung
Cancer Genomic Testing Medicine Market Outlook
5.3.3.1.
Market Size & Forecast
5.3.3.1.1.
By Value
5.3.3.2.
Market Share & Forecast
5.3.3.2.1.
By Technology
5.3.3.2.2.
By Sample Type
5.3.3.2.3.
By Panel Type
5.3.3.2.4.
By End-User
5.3.4.
Japan Lung Cancer
Genomic Testing Medicine Market Outlook
5.3.4.1.
Market Size & Forecast
5.3.4.1.1.
By Value
5.3.4.2.
Market Share & Forecast
5.3.4.2.1.
By Technology
5.3.4.2.2.
By Sample Type
5.3.4.2.3.
By Panel Type
5.3.4.2.4.
By End-User
5.3.5.
South Korea Lung
Cancer Genomic Testing Medicine Market Outlook
5.3.5.1.
Market Size & Forecast
5.3.5.1.1.
By Value
5.3.5.2.
Market Share & Forecast
5.3.5.2.1.
By Technology
5.3.5.2.2.
By Sample Type
5.3.5.2.3.
By Panel Type
5.3.5.2.4.
By End-User
6. Europe Lung Cancer Genomic Testing Medicine Market
Outlook
6.1.
Market Size &
Forecast
6.1.1.
By Value
6.2.
Market Share &
Forecast
6.2.1. By Technology
6.2.2. By Sample Type
6.2.3. By Panel Type
6.2.4. By End-User
6.2.5. By Country
6.3.
Europe: Country Analysis
6.3.1.
France Lung Cancer
Genomic Testing Medicine Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Technology
6.3.1.2.2.
By Sample Type
6.3.1.2.3.
By Panel Type
6.3.1.2.4.
By End-User
6.3.2.
Germany Lung Cancer
Genomic Testing Medicine Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Technology
6.3.2.2.2.
By Sample Type
6.3.2.2.3.
By Panel Type
6.3.2.2.4.
By End-User
6.3.3.
Spain Lung Cancer
Genomic Testing Medicine Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Technology
6.3.3.2.2.
By Sample Type
6.3.3.2.3.
By Panel Type
6.3.3.2.4.
By End-User
6.3.4.
Italy Lung Cancer
Genomic Testing Medicine Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Technology
6.3.4.2.2.
By Sample Type
6.3.4.2.3.
By Panel Type
6.3.4.2.4.
By End-User
6.3.5.
United Kingdom Lung
Cancer Genomic Testing Medicine Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Technology
6.3.5.2.2.
By Sample Type
6.3.5.2.3.
By Panel Type
6.3.5.2.4.
By End-User
7. North America Lung Cancer Genomic Testing Medicine Market
Outlook
7.1.
Market Size &
Forecast
7.1.1.
By Value
7.2.
Market Share &
Forecast
7.2.1. By Technology
7.2.2. By Sample Type
7.2.3. By Panel Type
7.2.4. By End-User
7.2.5.
By Country
7.3.
North America:
Country Analysis
7.3.1.
United States Lung
Cancer Genomic Testing Medicine Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Technology
7.3.1.2.2.
By Sample Type
7.3.1.2.3.
By Panel Type
7.3.1.2.4.
By End-User
7.3.2.
Mexico Lung Cancer
Genomic Testing Medicine Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Technology
7.3.2.2.2.
By Sample Type
7.3.2.2.3.
By Panel Type
7.3.2.2.4.
By End-User
7.3.3.
Canada Lung Cancer
Genomic Testing Medicine Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Technology
7.3.3.2.2.
By Sample Type
7.3.3.2.3.
By Panel Type
7.3.3.2.4.
By End-User
8. South America Lung Cancer Genomic Testing Medicine Market
Outlook
8.1.
Market Size &
Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Technology
8.2.2. By Sample Type
8.2.3. By Panel Type
8.2.4. By End-User
8.2.5.
By Country
8.3.
South America:
Country Analysis
8.3.1.
Brazil Lung Cancer
Genomic Testing Medicine Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Technology
8.3.1.2.2.
By Sample Type
8.3.1.2.3.
By Panel Type
8.3.1.2.4.
By End-User
8.3.2.
Argentina Lung
Cancer Genomic Testing Medicine Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Technology
8.3.2.2.2.
By Sample Type
8.3.2.2.3.
By Panel Type
8.3.2.2.4.
By End-User
8.3.3.
Colombia Lung Cancer
Genomic Testing Medicine Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Technology
8.3.3.2.2.
By Sample Type
8.3.3.2.3.
By Panel Type
8.3.3.2.4.
By End-User
9. Middle East and Africa Lung Cancer Genomic Testing
Medicine Market Outlook
9.1.
Market Size &
Forecast
9.1.1.
By Value
9.2.
Market Share &
Forecast
9.2.1. By Technology
9.2.2. By Sample Type
9.2.3. By Panel Type
9.2.4. By End-User
9.2.5.
By Country
9.3.
MEA: Country
Analysis
9.3.1.
South Africa Lung
Cancer Genomic Testing Medicine Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Technology
9.3.1.2.2.
By Sample Type
9.3.1.2.3.
By Panel Type
9.3.1.2.4.
By End-User
9.3.2.
Saudi Arabia Lung
Cancer Genomic Testing Medicine Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Technology
9.3.2.2.2.
By Sample Type
9.3.2.2.3.
By Panel Type
9.3.2.2.4.
By End-User
9.3.3.
UAE Lung Cancer
Genomic Testing Medicine Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Technology
9.3.3.2.2.
By Sample Type
9.3.3.2.3.
By Panel Type
9.3.3.2.4.
By End-User
10.
Market Dynamics
10.1.
Drivers
10.2.
Challenges
11.
Market Trends &
Developments
11.1.
Recent Developments
11.2.
Product Launches
11.3.
Mergers &
Acquisitions
12.
Global Lung Cancer
Genomic Testing Medicine Market: SWOT Analysis
13. Porter’s Five Forces Analysis
13.1.
Competition in the
Industry
13.2.
Potential of New
Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute
Product
14.
Competitive
Landscape
14.1. QIAGEN NV
14.1.1.
Business Overview
14.1.2.
Company Snapshot
14.1.3.
Product &
Services
14.1.5.
Financials (In case
of listed)
14.1.6.
Recent Developments
14.1.7.
SWOT Analysis
14.2. Agilent Technologies
Inc.
14.3. Thermo Fisher
Scientific Inc.
14.4. Quest Diagnostics
Incorporated
14.5. Laboratory Corporation
of America Holdings
14.6. CENTOGENE N.V.
14.7. BGI Genomics Co. Ltd.
14.8. CeGaT GmbH
14.9. Illumina Inc.
14.10.F. Hoffmann-La Roche Ltd
15.
Strategic Recommendations
16.
About Us & Disclaimer